tafasitamab
Sign in to saveAlso known as Minjuvi
Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.
Medication
- Generic name
- Tafasitamab-Cxix
- Brand names
- Monjuvi
- Route
- Intravenous
- Type
- Human Prescription Drug
- Manufacturer
- Incyte Corporation
Indications: 1 INDICATIONS AND USAGE MONJUVI is a CD19-directed cytolytic antibody indicated: in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who… (per FDA label)
Clinical Trials
54 registered- PHASE2ACTIVE_NOT_RECRUITINGStudy of Acalabrutinib and Tafasitamab in MZL PatientsInternational Extranodal Lymphoma Study Group (IELSG) · NCT04646395
- PHASE3ACTIVE_NOT_RECRUITINGTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsIncyte Corporation · NCT04824092
- PHASE2NOT_YET_RECRUITINGA Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideInstitute of Hematology & Blood Diseases Hospital, China · NCT07585747
- PHASE2ACTIVE_NOT_RECRUITINGRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyM.D. Anderson Cancer Center · NCT04978584
- PHASE2RECRUITINGExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabIncyte Corporation · NCT06465433
- PHASE2RECRUITINGTafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaDavid Bond, MD · NCT05821088
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Names
- References
- External links
Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.
Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.
Excerpted from Wikipedia’s “tafasitamab” article, available under the CC BY-SA 4.0 licence.